Delcath Systems to Present at BTIG MedTech Conference
Event summary
- Delcath Systems (Nasdaq: DCTH) will attend the BTIG 13th Annual MedTech Conference on January 27, 2026.
- The company focuses on interventional oncology for liver cancer treatments.
- Key products include HEPZATO KIT (FDA-approved) and CHEMOSAT (EU-approved).
- HEPZATO KIT is approved for metastatic uveal melanoma with specific conditions.
The big picture
Delcath Systems' participation in the BTIG MedTech Conference underscores its focus on expanding its interventional oncology footprint. The company's proprietary treatments for liver cancer are positioned at the intersection of drug-device innovation, a growing segment in the MedTech industry. With HEPZATO KIT already FDA-approved and CHEMOSAT established in Europe, Delcath is poised to leverage this platform to drive further market engagement and potential partnerships.
What we're watching
- Regulatory Expansion
- Whether Delcath can secure additional approvals for HEPZATO KIT beyond its current indication.
- Market Penetration
- The pace at which Delcath can increase adoption of its treatments in major medical centers.
- Competitive Dynamics
- How Delcath positions itself against emerging liver cancer treatments in the MedTech space.
Related topics